NovoCure
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, NovoCure sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
NovoCure: 11 sponsored US clinical trials, 2 recruiting.
NovoCure sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 9 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Glioblastoma Multiforme, with 1 trials.
Top-decile sponsor footprint
NovoCure ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
11 total, page 1 of 1
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NCT04471844
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
NCT04892472
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
NCT03940196
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NCT03377491
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NCT02973789
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
NCT02831959
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
NCT01756729
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
NCT00916409
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
NCT00379470
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
Where NovoCure enrollment is open (later-stage tilt)
2 recruiting of 11 indexed (18% open); 6 completed (55%).
Phase mix: 9 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Recurrent Glioblastoma Multiforme (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NovoCure: open-pipeline peers nationwide
Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
NovoCure sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 trials (± recruiting share)
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Burke Medical Research Institute · 18% recruiting · 11 trials
- Grand Valley State University · 18% recruiting · 11 trials
- Imunon · 18% recruiting · 11 trials
- InventisBio Co. · 18% recruiting · 11 trials
Related
What to do with this NovoCure page
11 registered trials is a research-attention snapshot, not an endorsement of NovoCure or any single study.
- 2 of NovoCure's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent Glioblastoma Multiforme is the condition NovoCure studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Glioblastoma Multiforme trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NovoCure pipeline card: 11 registered trials from official public datasets.Report a data error.